ReviewPLoS pathogens2025
Phage therapy for Klebsiella pneumoniae: Understanding bacteria-phage interactions for therapeutic innovations.
Review in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Innovative Applications of Artificial Intelligence in Bacteriophage Research: A New Chapter in Future Medicine.Microorganisms · 2026Review
- Differential virulence potential of different clades of multidrug-resistantMicrobiology spectrum · 2026Article
- Isolation and Genomic Characterisation of Five Novel Lytic Bacteriophages Infecting the Emerging PathogenViruses · 2026Article
- A comprehensive phage-bacteria interaction atlas links phage lineage and capsule serotype to genome-guided machine learning prediction inbioRxiv : the preprint server for biology · 2026Article
- Article
- Cross-family and phage-specific gene requirements for Klebsiella infection revealed by scalable RB-TnSeq genetic screens.PLoS genetics · 2026Article
- GMMA as delivery system for Klebsiella pneumoniae O-antigens and K-antigens.Scientific reports · 2026Article
- Characterization of novel phage Henuyfy11N: a potential therapeutic agent against extended-spectrum β-lactamase (ESBL)-producingMicrobiology spectrum · 2026Article
- Programmable Klebsiella pneumoniae Phage Tropism Enabled by Scalable Receptor-Binding Protein Mining and Modular Assembly.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Differential virulence potential of different clades of multidrug-resistantmedRxiv : the preprint server for health sciences · 2026Article
- A novel phage preparation capable of simultaneously inhibiting both K1 and K2 serotypes ofApplied and environmental microbiology · 2026Article
- Isolation and characterization of lytic bacteriophages with therapeutic potential against multidrug resistant Klebsiella pneumoniae from Ethiopia.Scientific reports · 2026Article
- Molecular Insights into Carbapenem Resistance inInternational journal of molecular sciences · 2026Review
- Review
- Co-Occurrence of Resistance to Aminoglycosides and Carbapenems inInternational journal of microbiology · 2026Review
- Phage therapy againstFrontiers in microbiology · 2026Review
- Antibiotic resistance inFrontiers in microbiology · 2026Review
- Evolutionary Origins and Virulence Determinants of ST25 HypervirulentTransboundary and emerging diseases · 2026Article
- Bacteriophage therapy beyond antibiotics: emerging innovations for infectious and non-infectious diseases.Frontiers in cellular and infection microbiology · 2026Review
- Genomic epidemiology of multidrug-resistantAIMS microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Klebsiella pneumoniae (KP) is a Gram-negative bacterium that commonly resides in the human gastrointestinal tract and can also act as an opportunistic pathogen and cause extra-intestinal infections. KP poses a global health threat because it causes both hospital- and community-acquired infections in immune-competent and immunocompromised hosts. These infections can be multidrug-resistant and/or hypervirulent, making KP infections difficult to treat and deadly. In the absence of effective treatments for recalcitrant KP infections, bacteriophage (phage) therapy is gaining attention as a promising alternative. In this review, we evaluate KP epidemiology and epitope diversity, discuss interactions between KP-targeting phages and their bacterial hosts from an eco-evolutionary perspective, and summarize recent efforts in phage therapy for treating KP infections. We also discuss novel approaches, including genetic engineering and machine learning, as initial steps toward developing KP-targeting phage therapy as a precision medicine approach for an emerging and dangerous pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.